ImmunityBio, Inc. Common Stock
Here’s whether ImmunityBio, Inc. Common Stock (IBRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 48 — healthy momentum range; strong 1-year return of +122.6%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-1.78% over 10 days); 3-month momentum negative (-13.5%). Currently 42.9% off its 52-week high. Score: +1/7.
IBRX is holding above its long-term 200-day MA ($5.04) but has slipped below the 50-day MA ($7.55), pointing to short-term weakness in an otherwise intact trend. An RSI of 47.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +122.6% compares to +22.9% for SPY (beat the market by 99.7%). The current 42.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.